Presence of BRAF mutations in benign and dysplastic nevi [39] supports the hypothesis that activation of the NRAS-BRAF-ERK pathway is not sufficient to induce the malignant process and fully transform proliferating melanocytes, but requires additional, cooperating de-regulative events. Here, MAPK1 is linked to dysplastic nevus.